Exogenous melatonin as potential adjuvant in anti-SarsCov2 vaccines

Maestroni, Georges J. M.

doi:10.1007/s11481-020-09956-1

Cited by 12 publications

(15 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Above all, the safety and tolerability profile is favorable for melatonin use in humans with a low incidence of mild adverse effects mostly associated with sleep structure alternations [31,67].…”

Section: Melatonin-adjuvant In Covid-19 Clinical Managementmentioning

confidence: 99%

“…Melatonin is known to enhance the immune response to vaccines. Its use may act as an adjuvant in anti-SARS-CoV-2 vaccination, increasing the strength and duration of the immunity acquired [28,67]. Melatonin counteracts immunosuppression, including the one resulting from corticosteroid use, increasing the IgG-expressing B cells, IgG antibody response, and peripheral blood CD4+ T lymphocytes.…”

Section: Melatonin-anti-sars-cov-2 Vaccine Adjuvantmentioning

confidence: 99%

See 1 more Smart Citation

Melatonin as a Potential Adjuvant Treatment for COVID-19 beyond Sleep Disorders

Wichniak

Kania

Siemiński

et al. 2021

IJMS

View full text Add to dashboard Cite

Melatonin is registered to treat circadian rhythm sleep–wake disorders and insomnia in patients aged 55 years and over. The essential role of the circadian sleep rhythm in the deterioration of sleep quality during COVID-19 confinement and the lack of an adverse effect of melatonin on respiratory drive indicate that melatonin has the potential to be a recommended treatment for sleep disturbances related to COVID-19. This review article describes the effects of melatonin additional to its sleep-related effects, which make this drug an attractive therapeutic option for treating patients with COVID-19. The preclinical data suggest that melatonin may inhibit COVID-19 progression. It may lower the risk of the entrance of the SARS-CoV-2 virus into cells, reduce uncontrolled hyper-inflammation and the activation of immune cells, limit the damage of tissues and multiorgan failure due to the action of free radicals, and reduce ventilator-induced lung injury and the risk of disability resulting from fibrotic changes within the lungs. Melatonin may also increase the efficacy of COVID-19 vaccination. The high safety profile of melatonin and its potential anti-SARS-CoV-2 effects make this molecule a preferable drug for treating sleep disturbances in COVID-19 patients. However, randomized clinical trials are needed to verify the clinical usefulness of melatonin in the treatment of COVID-19.

show abstract

Section: Melatonin-adjuvant In Covid-19 Clinical Managementmentioning

confidence: 99%

Section: Melatonin-anti-sars-cov-2 Vaccine Adjuvantmentioning

confidence: 99%

Melatonin as a Potential Adjuvant Treatment for COVID-19 beyond Sleep Disorders

Wichniak

Kania

Siemiński

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

“…However, even if such a vaccine is established, vaccine efficacy may be inferior for the elderly and other high-risk population groups compared to people who are healthy and young. Melatonin may help to close the gap in this respect [109].…”

Section: Melatonin As An Adjuvant In Anti-sars-cov-2 Vaccinationmentioning

confidence: 99%

“…Administration of exogenous melatonin could increase the potency of the immune response and the duration of the immunity induced by the vaccine. Moreover, due to its antioxidant properties and its pleiotropic effect on the immune system, melatonin could also prevent the adverse effects of the vaccine [109].…”

Section: Melatonin As An Adjuvant In Anti-sars-cov-2 Vaccinationmentioning

confidence: 99%

Can Melatonin Be a Potential “Silver Bullet” in Treating COVID-19 Patients?

2020

View full text Add to dashboard Cite

The therapeutic potential of melatonin as a chronobiotic cytoprotective agent to counteract the consequences of COVID-19 infections has been advocated. Because of its wide-ranging effects as an antioxidant, anti-inflammatory, and immunomodulatory compound, melatonin could be unique in impairing the consequences of SARS-CoV-2 infection. Moreover, indirect evidence points out to a possible antiviral action of melatonin by interfering with SARS-CoV-2/angiotensin-converting enzyme 2 association. Melatonin is also an effective chronobiotic agent to reverse the circadian disruption of social isolation and to control delirium in severely affected patients. As a cytoprotector, melatonin serves to combat several comorbidities such as diabetes, metabolic syndrome, and ischemic and non-ischemic cardiovascular diseases, which aggravate COVID-19 disease. In view of evidence on the occurrence of neurological sequels in COVID-19-infected patients, another putative application of melatonin emerges based on its neuroprotective properties. Since melatonin is an effective means to control cognitive decay in minimal cognitive impairment, its therapeutic significance for the neurological sequels of SARS-CoV-2 infection should be considered. Finally, yet importantly, exogenous melatonin can be an adjuvant capable of augmenting the efficacy of anti-SARS-CoV-2 vaccines. We discuss in this review the experimental evidence suggesting that melatonin is a potential “silver bullet” in the COVID 19 pandemic.

show abstract

“…Likewise, individuals on melatonin treatment, along with other pharmacological, genre, ethnicity, and age features, have been positively discriminated as reduced-risk for COVID-19 by a logistic regression algorithm over more than 11,000 people [28]. Moreover, the translational applicability of this molecule stands out over other therapy drug candidates to effectively and safely curtail the COVID-19 pandemic [10,25,29], as well as to enhance the immune response to vaccination [16,[30][31][32].…”

Section: Introductionmentioning

confidence: 99%

The Coronavirus Disease 2019 (COVID-19): Key Emphasis on Melatonin Safety and Therapeutic Efficacy

et al. 2021

View full text Add to dashboard Cite

Viral infections constitute a tectonic convulsion in the normophysiology of the hosts. The current coronavirus disease 2019 (COVID-19) pandemic is not an exception, and therefore the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, like any other invading microbe, enacts a generalized immune response once the virus contacts the body. Melatonin is a systemic dealer that does not overlook any homeostasis disturbance, which consequently brings into play its cooperative triad, antioxidant, anti-inflammatory, and immune-stimulant backbone, to stop the infective cycle of SARS-CoV-2 or any other endogenous or exogenous threat. In COVID-19, the corporal propagation of SARS-CoV-2 involves an exacerbated oxidative activity and therefore the overproduction of great amounts of reactive oxygen and nitrogen species (RONS). The endorsement of melatonin as a possible protective agent against the current pandemic is indirectly supported by its widely demonstrated beneficial role in preclinical and clinical studies of other respiratory diseases. In addition, focusing the therapeutic action on strengthening the host protection responses in critical phases of the infective cycle makes it likely that multi-tasking melatonin will provide multi-protection, maintaining its efficacy against the virus variants that are already emerging and will emerge as long as SARS-CoV-2 continues to circulate among us.

show abstract

Exogenous melatonin as potential adjuvant in anti-SarsCov2 vaccines

Cited by 12 publications

References 16 publications

Melatonin as a Potential Adjuvant Treatment for COVID-19 beyond Sleep Disorders

Melatonin as a Potential Adjuvant Treatment for COVID-19 beyond Sleep Disorders

Can Melatonin Be a Potential “Silver Bullet” in Treating COVID-19 Patients?

The Coronavirus Disease 2019 (COVID-19): Key Emphasis on Melatonin Safety and Therapeutic Efficacy

Contact Info

Product

Resources

About